241 related articles for article (PubMed ID: 22248260)
1. Platelet hyperaggregability in high-fat fed rats: a role for intraplatelet reactive-oxygen species production.
Monteiro PF; Morganti RP; Delbin MA; Calixto MC; Lopes-Pires ME; Marcondes S; Zanesco A; Antunes E
Cardiovasc Diabetol; 2012 Jan; 11():5. PubMed ID: 22248260
[TBL] [Abstract][Full Text] [Related]
2. Activation of haem-oxidized soluble guanylyl cyclase with BAY 60-2770 in human platelets lead to overstimulation of the cyclic GMP signaling pathway.
Mendes-Silverio CB; Leiria LO; Morganti RP; Anhê GF; Marcondes S; Mónica FZ; De Nucci G; Antunes E
PLoS One; 2012; 7(11):e47223. PubMed ID: 23144808
[TBL] [Abstract][Full Text] [Related]
3. The anti-aggregating effect of BAY 41-2272, a stimulator of soluble guanylyl cyclase, requires the presence of nitric oxide.
Roger S; Badier-Commander C; Paysant J; Cordi A; Verbeuren TJ; Félétou M
Br J Pharmacol; 2010 Nov; 161(5):1044-58. PubMed ID: 20977455
[TBL] [Abstract][Full Text] [Related]
4. Differentiation of cGMP-dependent and -independent nitric oxide effects on platelet apoptosis and reactive oxygen species production using platelets lacking soluble guanylyl cyclase.
Rukoyatkina N; Walter U; Friebe A; Gambaryan S
Thromb Haemost; 2011 Nov; 106(5):922-33. PubMed ID: 21800013
[TBL] [Abstract][Full Text] [Related]
5. Antiplatelet properties of a novel, non-NO-based soluble guanylate cyclase activator, BAY 41-2272.
Hobbs AJ; Moncada S
Vascul Pharmacol; 2003 Oct; 40(3):149-54. PubMed ID: 13678646
[TBL] [Abstract][Full Text] [Related]
6. Soluble guanylyl cyclase is the only enzyme responsible for cyclic guanosine monophosphate synthesis in human platelets.
Gambaryan S; Subramanian H; Rukoyatkina N; Herterich S; Walter U
Thromb Haemost; 2013 May; 109(5):973-5. PubMed ID: 23467662
[No Abstract] [Full Text] [Related]
7. Analysis of nitric oxide-sensitive guanylyl cyclase in human platelets before and after aggregation.
Kempfert J; Behrends S
Platelets; 2003; 14(7-8):429-35. PubMed ID: 14713512
[TBL] [Abstract][Full Text] [Related]
8. Carbon monoxide released by CORM-3 inhibits human platelets by a mechanism independent of soluble guanylate cyclase.
Chlopicki S; Olszanecki R; Marcinkiewicz E; Lomnicka M; Motterlini R
Cardiovasc Res; 2006 Jul; 71(2):393-401. PubMed ID: 16713591
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of rat platelet aggregation by the diazeniumdiolate nitric oxide donor MAHMA NONOate.
Homer KL; Wanstall JC
Br J Pharmacol; 2002 Dec; 137(7):1071-81. PubMed ID: 12429580
[TBL] [Abstract][Full Text] [Related]
10. Anti-aggregating effect of BAY 58-2667, an activator of soluble guanylyl cyclase.
Roger S; Paysant J; Badier-Commander C; Cordi A; Verbeuren TJ; Félétou M
Vascul Pharmacol; 2010; 53(5-6):281-7. PubMed ID: 20933607
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of N-acetylcysteine as an antiplatelet agent in patients with type-2 diabetes.
Gibson KR; Winterburn TJ; Barrett F; Sharma S; MacRury SM; Megson IL
Cardiovasc Diabetol; 2011 May; 10():43. PubMed ID: 21600014
[TBL] [Abstract][Full Text] [Related]
12. Suppressed anti-aggregating and cGMP-elevating effects of sodium nitroprusside in platelets from patients with stable angina pectoris.
Chirkov YY; Chirkova LP; Horowitz JD
Naunyn Schmiedebergs Arch Pharmacol; 1996 Oct; 354(4):520-5. PubMed ID: 8897457
[TBL] [Abstract][Full Text] [Related]
13. Soluble guanylyl cyclase (sGC) degradation and impairment of nitric oxide-mediated responses in urethra from obese mice: reversal by the sGC activator BAY 60-2770.
Alexandre EC; Leiria LO; Silva FH; Mendes-Silvério CB; Calmasini FB; Davel AP; Mónica FZ; De Nucci G; Antunes E
J Pharmacol Exp Ther; 2014 Apr; 349(1):2-9. PubMed ID: 24421320
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of relaxant activity of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in rat tracheal smooth muscle.
Toque HA; Mónica FZ; Morganti RP; De Nucci G; Antunes E
Eur J Pharmacol; 2010 Oct; 645(1-3):158-64. PubMed ID: 20670622
[TBL] [Abstract][Full Text] [Related]
15. Platelet resistance to the antiaggregating effect of N-acetyl-L-cysteine in obese, insulin-resistant subjects.
Anfossi G; Russo I; Massucco P; Mattiello L; Trovati M
Thromb Res; 2003 Apr; 110(1):39-46. PubMed ID: 12877907
[TBL] [Abstract][Full Text] [Related]
16. Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress.
Zhou Z; Pyriochou A; Kotanidou A; Dalkas G; van Eickels M; Spyroulias G; Roussos C; Papapetropoulos A
Am J Physiol Heart Circ Physiol; 2008 Oct; 295(4):H1763-71. PubMed ID: 18757489
[TBL] [Abstract][Full Text] [Related]
17. Soluble guanylate cyclase chronic stimulation effects on cardiovascular reactivity in cafeteria diet-induced rat model of metabolic syndrome.
Doghri Y; Dubreil L; Lalanne V; Hélissen O; Fleurisson R; Thorin C; Desfontis JC; Mallem MY
Eur J Pharmacol; 2021 May; 899():173978. PubMed ID: 33691164
[TBL] [Abstract][Full Text] [Related]
18. Soluble guanylyl cyclase activation with HMR1766 attenuates platelet activation in diabetic rats.
Schäfer A; Flierl U; Kobsar A; Eigenthaler M; Ertl G; Bauersachs J
Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2813-8. PubMed ID: 17023677
[TBL] [Abstract][Full Text] [Related]
19. Lipopolysaccharide treatment reduces rat platelet aggregation independent of intracellular reactive-oxygen species generation.
Lopes-Pires ME; Casarin AL; Pereira-Cunha FG; Lorand-Metze I; Antunes E; Marcondes S
Platelets; 2012; 23(3):195-201. PubMed ID: 21806496
[TBL] [Abstract][Full Text] [Related]
20. Increase in reactivity of human platelet guanylate cyclase during aggregation potentiates the disaggregating capacity of sodium nitroprusside.
Chirkov YY; Belushkina NN; Tyshchuk IA; Severina IS; Horowitz JD
Clin Exp Pharmacol Physiol; 1991 Jul; 18(7):517-24. PubMed ID: 1680588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
